Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q1 2014 · 10-Q
Revenue$208.36K$208.36K+82.3% vs Q1 2013 Net Income$62.78K$62.78KN/M vs Q1 2013 EPS Diluted$0.02$0.02N/M vs Q1 2013 Gross Profit$154,158+48.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flow$36,999+505.6% Margins · derivedGross margin74.0%−16.9 pt vs Q1 2013
Operating margin31.6%+873.9 pt vs Q1 2013
Net margin30.1%+882.3 pt vs Q1 2013
ended Mar 31, 2014 · filed May 14, 2014 · 44 d after period end